Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Bibliographic Details
Main Authors: DiNardo, C, Stein, A, Stein, E, Fathi, A, Frankfurt, O, Schuh, A, Doehner, H, Martinelli, G, Patel, P, Raffoux, E, Tan, P, Zeidan, A, De Botton, S, Kantarjian, H, Stone, R, Lam, D, Wang, X, Gong, J, Kapsalis, S, Hickman, D, Zhang, V, Winkler, T, Wu, B, Vyas, P
Format: Conference item
Published: Springer 2019

Similar Items

Similar Items